Sichuan Kelun-Biotech Biopharmaceutical (6990.HK) Earnings Analysis

Sichuan Kelun-Biotech Biopharmaceutical (6990.HK) next reports earnings on 2026-08-24, consensus EPS 0.2696 HKD. Last quarter (2026-03-23) it beat with EPS -1.00852 HKD vs -1.48229 HKD est (+32%). It has beaten estimates in 1/1 recent quarters (100%). Trailing P/E -250.26.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 6990.HK next report earnings?

Next earnings date2026-08-24
Consensus EPS estimate0.2696 HKD
Revenue estimate1.27B

6990.HK earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-23-1.00852 HKD-1.48229 HKD+32%Beat

Beat rate: 1/1 (100%) over reported quarters with consensus data.

6990.HK valuation and analyst view

Trailing P/E-250.26
Trailing EPS-1.79428 HKD
Price / book21.59
Dividend yield0.00%
Market cap120.56B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Sichuan Kelun-Biotech Biopharmaceutical (6990.HK)'s next earnings date?

Sichuan Kelun-Biotech Biopharmaceutical is next scheduled to report on 2026-08-24, with a consensus EPS estimate of 0.2696 HKD and revenue estimate of 1.27B.

Did 6990.HK beat earnings last quarter?

In its 2026-03-23 report, 6990.HK posted EPS of -1.00852 HKD versus a -1.48229 HKD estimate — a beat of 32%.

What is 6990.HK's earnings track record?

Over the last 1 reported quarters with consensus data, 6990.HK beat estimates 1 times (100%).

What is 6990.HK's current P/E ratio and EPS?

6990.HK trades at a trailing P/E of -250.26 on trailing EPS of -1.7942810577646615 HKD.

What do analysts rate 6990.HK?

6990.HK has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.